NCT05236517View on ClinicalTrials.gov

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

September 29, 2022

Study Completion Date

November 7, 2022

Conditions

Obesity

Interventions

DRUG

Semaglutide D Dose 1

Tablet given orally

DRUG

Semaglutide D Dose 2

Tablet given orally

DRUG

Semaglutide D Dose 3

Tablet given orally

DRUG

Semaglutide C Dose 4

Tablet given orally

DRUG

Semaglutide C Dose 5 (50 mg)

Tablet given orally

DRUG

Placebo (Semaglutide C)

Tablet given orally

DRUG

Placebo ( Semaglutide D)

Tablet given orally

Trial Locations (1)

14050

Parexel International GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT05236517 - A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity | Biotech Hunter | Biotech Hunter